An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours.
An enzyme-linked immunosorbent assay (ELISA) has been developed for measuring the in vivo binding of a hexafluorinated 2-nitroimidazole (CCI-103F) in tumour tissue biopsies. The binding of CCI-103F is believed to reflect the presence of hypoxia in tumours. The ELISA provides a sensitive and convenient method of measuring CCI-103F binding which does not require the injection of radioactive reagents. The ELISA is based on reagents prepared from synthetic antigens formed by the reductive activation and binding of CCI-103F to proteins in novel test tube experiments. Calibration of the ELISA involved comparing the ELISA with the radioactivity contained either in protein-CCI-103F adducts formed in vitro with tritiated CCI-103F or in tissues isolated from a tumour-bearing dog which had been injected with tritium-labelled CCI-103F. The two approaches to calibration are compared. The scope and limitation of the ELISA for measuring the binding of CCI-103F is discussed and an example of the application of the ELISA to measuring changes in tumour hypoxia in canine patients undergoing fractionated radiation therapy is presented.
Raleigh
J A
JA
Radiation Oncology Department, UNC School of Medicine, Chapel Hill 27599-7512.
La Dine
J K
JK
Cline
J M
JM
Thrall
D E
DE
D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism*; D002138:Calibration; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D000860:Hypoxia / Q000175:diagnosis / Q000378:metabolism*; D009369:Neoplasms / Q000737:chemistry / Q000378:metabolism* / Q000662:veterinary*; D009593:Nitroimidazoles / Q000378:metabolism* / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014316:Tritium; D005466:Fluorocarbons
D014408:Biomarkers, Tumor; D009593:Nitroimidazoles; D014316:Tritium; C049948:CCI 103F; D005466:Fluorocarbons